Concepts (146)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Embolism | 11 | 2018 | 2375 | 1.880 |
Why?
|
| Health Care Costs | 8 | 2019 | 3208 | 0.720 |
Why?
|
| Cost of Illness | 2 | 2019 | 1860 | 0.680 |
Why?
|
| Multiple Sclerosis | 4 | 2014 | 3079 | 0.670 |
Why?
|
| Walking | 2 | 2014 | 1180 | 0.570 |
Why?
|
| Acetanilides | 2 | 2014 | 168 | 0.540 |
Why?
|
| Quality of Life | 7 | 2019 | 12802 | 0.520 |
Why?
|
| Warfarin | 3 | 2018 | 1497 | 0.520 |
Why?
|
| Markov Chains | 3 | 2018 | 969 | 0.510 |
Why?
|
| Anticoagulants | 5 | 2020 | 4600 | 0.500 |
Why?
|
| Sodium Channel Blockers | 1 | 2015 | 176 | 0.500 |
Why?
|
| Thrombectomy | 1 | 2018 | 680 | 0.440 |
Why?
|
| Cardiovascular Agents | 2 | 2018 | 850 | 0.440 |
Why?
|
| Severity of Illness Index | 7 | 2018 | 15535 | 0.420 |
Why?
|
| Risk Assessment | 8 | 2018 | 23336 | 0.420 |
Why?
|
| Insurance Claim Review | 1 | 2017 | 720 | 0.420 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 1671 | 0.400 |
Why?
|
| Cost-Benefit Analysis | 8 | 2018 | 5388 | 0.380 |
Why?
|
| Drug Costs | 3 | 2016 | 1105 | 0.370 |
Why?
|
| Hospitalization | 4 | 2019 | 10259 | 0.360 |
Why?
|
| Coronary Thrombosis | 1 | 2013 | 495 | 0.360 |
Why?
|
| Mobility Limitation | 1 | 2014 | 409 | 0.360 |
Why?
|
| Hemorrhage | 3 | 2018 | 3461 | 0.360 |
Why?
|
| Standard of Care | 1 | 2014 | 564 | 0.360 |
Why?
|
| Attitude | 1 | 2014 | 776 | 0.330 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 1239 | 0.330 |
Why?
|
| Automobile Driving | 1 | 2014 | 431 | 0.320 |
Why?
|
| Health Status Indicators | 1 | 2014 | 970 | 0.320 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 1188 | 0.320 |
Why?
|
| Risk-Taking | 1 | 2014 | 986 | 0.320 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 2043 | 0.290 |
Why?
|
| Piperazines | 2 | 2014 | 2488 | 0.280 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 2214 | 0.280 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2017 | 1683 | 0.250 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1956 | 0.250 |
Why?
|
| Hospital Mortality | 6 | 2019 | 5316 | 0.250 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 1980 | 0.240 |
Why?
|
| Students | 1 | 2014 | 1647 | 0.230 |
Why?
|
| Brain Ischemia | 1 | 2018 | 3265 | 0.230 |
Why?
|
| Data Collection | 1 | 2013 | 3339 | 0.230 |
Why?
|
| Veterans | 1 | 2017 | 2519 | 0.220 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 4253 | 0.220 |
Why?
|
| Databases, Factual | 2 | 2017 | 7730 | 0.210 |
Why?
|
| Models, Economic | 2 | 2017 | 712 | 0.210 |
Why?
|
| Coronary Angiography | 1 | 2013 | 4576 | 0.200 |
Why?
|
| Registries | 2 | 2018 | 8091 | 0.200 |
Why?
|
| Stents | 1 | 2013 | 3282 | 0.200 |
Why?
|
| Prognosis | 7 | 2019 | 29060 | 0.190 |
Why?
|
| Neoplasms | 3 | 2020 | 21696 | 0.190 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 3966 | 0.190 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11525 | 0.180 |
Why?
|
| Survival Rate | 4 | 2019 | 12788 | 0.170 |
Why?
|
| Male | 21 | 2019 | 350115 | 0.170 |
Why?
|
| Humans | 35 | 2020 | 744366 | 0.170 |
Why?
|
| Female | 23 | 2019 | 380193 | 0.160 |
Why?
|
| Melanoma | 1 | 2017 | 5511 | 0.160 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 127 | 0.160 |
Why?
|
| Health Status | 3 | 2019 | 4034 | 0.160 |
Why?
|
| Aged | 14 | 2020 | 163288 | 0.160 |
Why?
|
| Middle Aged | 15 | 2019 | 213390 | 0.150 |
Why?
|
| Exercise | 1 | 2014 | 5615 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 9955 | 0.150 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 4257 | 0.150 |
Why?
|
| Equipment Safety | 1 | 2018 | 263 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 281 | 0.140 |
Why?
|
| United States | 10 | 2020 | 69872 | 0.140 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2017 | 841 | 0.140 |
Why?
|
| Chronic Disease | 3 | 2015 | 9145 | 0.130 |
Why?
|
| Stroke | 1 | 2018 | 9981 | 0.130 |
Why?
|
| Enoxaparin | 1 | 2017 | 377 | 0.130 |
Why?
|
| Vital Signs | 1 | 2016 | 142 | 0.120 |
Why?
|
| Drugs, Generic | 1 | 2019 | 421 | 0.120 |
Why?
|
| Dacarbazine | 1 | 2017 | 566 | 0.120 |
Why?
|
| Carboplatin | 1 | 2017 | 801 | 0.120 |
Why?
|
| Retrospective Studies | 9 | 2019 | 77460 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 3799 | 0.110 |
Why?
|
| International Normalized Ratio | 1 | 2014 | 367 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 875 | 0.110 |
Why?
|
| Prescription Drugs | 1 | 2019 | 595 | 0.100 |
Why?
|
| Vitamin K | 1 | 2014 | 295 | 0.100 |
Why?
|
| New England | 1 | 2014 | 1022 | 0.090 |
Why?
|
| Vascular Surgical Procedures | 1 | 2019 | 1476 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2014 | 12025 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 9274 | 0.090 |
Why?
|
| Paclitaxel | 1 | 2017 | 1708 | 0.090 |
Why?
|
| Placebos | 1 | 2014 | 1676 | 0.090 |
Why?
|
| Risk Factors | 4 | 2018 | 72296 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6896 | 0.090 |
Why?
|
| Adult | 10 | 2020 | 214052 | 0.090 |
Why?
|
| Heparin | 1 | 2016 | 1637 | 0.080 |
Why?
|
| Universities | 1 | 2014 | 951 | 0.080 |
Why?
|
| Accidents, Traffic | 1 | 2014 | 819 | 0.080 |
Why?
|
| Metformin | 1 | 2015 | 836 | 0.080 |
Why?
|
| Population Surveillance | 1 | 2018 | 2616 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 1680 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 11031 | 0.070 |
Why?
|
| Length of Stay | 2 | 2017 | 6311 | 0.070 |
Why?
|
| Comorbidity | 2 | 2018 | 10388 | 0.070 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2020 | 339 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2014 | 1828 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2018 | 57776 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2014 | 1425 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 2725 | 0.060 |
Why?
|
| Cause of Death | 1 | 2015 | 3582 | 0.060 |
Why?
|
| Treatment Outcome | 5 | 2019 | 63107 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 12356 | 0.060 |
Why?
|
| Health Surveys | 1 | 2014 | 4036 | 0.060 |
Why?
|
| Predictive Value of Tests | 2 | 2017 | 15078 | 0.060 |
Why?
|
| Linear Models | 1 | 2014 | 5953 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 25039 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2018 | 11726 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 2873 | 0.050 |
Why?
|
| Self Report | 1 | 2014 | 3553 | 0.050 |
Why?
|
| Prevalence | 1 | 2019 | 15221 | 0.050 |
Why?
|
| Time Factors | 2 | 2014 | 40075 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 10943 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 12244 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 7785 | 0.040 |
Why?
|
| Mental Health | 1 | 2014 | 3010 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 40559 | 0.040 |
Why?
|
| Adolescent | 3 | 2017 | 85779 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 20824 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 53290 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 6773 | 0.040 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2019 | 336 | 0.040 |
Why?
|
| Receptor, erbB-2 | 2 | 2016 | 2417 | 0.030 |
Why?
|
| Neoplasm Metastasis | 2 | 2016 | 4851 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 13693 | 0.030 |
Why?
|
| Systole | 1 | 2015 | 958 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 39052 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 1655 | 0.020 |
Why?
|
| Logistic Models | 2 | 2016 | 13409 | 0.020 |
Why?
|
| Probability | 1 | 2016 | 2506 | 0.020 |
Why?
|
| Health Resources | 1 | 2016 | 911 | 0.020 |
Why?
|
| Drug Monitoring | 1 | 2014 | 956 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2015 | 861 | 0.020 |
Why?
|
| Young Adult | 1 | 2014 | 56429 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 6489 | 0.020 |
Why?
|
| Body Weight | 1 | 2015 | 4671 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 3020 | 0.010 |
Why?
|
| Medicare | 1 | 2020 | 6566 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2015 | 8551 | 0.010 |
Why?
|
| Disease Progression | 1 | 2016 | 13286 | 0.010 |
Why?
|
| Age Factors | 1 | 2015 | 18373 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 19905 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 7658 | 0.010 |
Why?
|
Concepts
(146)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(1)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_